摘要:
The present invention relates to compounds of the general formula wherein
R 1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, amino, nitro, cyano, lower alkyl-amino, di-lower alkyl-amino or halogen; R 2 is hydrogen, lower alkyl, amino, pyrrolidin-3-ol, pyrrolidin-2-yl-methanol or -NHCH 2 CHROH; R 3 is hydrogen or halogen; R is hydrogen, lower alkyl or -CH 2 OH; n is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which have a key function in modulating neuronal activity and plasticity in mediating processes underlying development of CNS as well as learning and memory formation.
摘要:
The present invention relates to compounds of the general formula wherein
X is -O-, -NH-, -CH 2 -, -CH=, -CO 2 -, -CONH-, -CON(lower alkyl)-, -S- and -SO 2 -; R 1 - R 4 are, independently from each other hydrogen, halogen, hydroxy, amino, nitro, lower-alkyl-sulfonylamido, 1- or 2-imidazolyl, 1-(1,2,4-triazolyl) or acetamido; R 5 , R 6 are, independently from each other hydrogen, lower-alkyl, hydroxy, lower alkoxy or oxo; R 7 -R 10 are, independently from each other hydrogen, lower-alkyl, halogen, trifluoromethyl or lower-alkoxy; n is 0 or 1; and to pharmaceutically acceptable acid addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers.
摘要:
The present invention relates to the use of tetrahydroisoquinoline derivatives of the general formula wherein
A is aryl R 1 is hydrogen, hydroxy, lower alkyl, lower alkoxy, R-CO- or R-COO-, wherein R is lower alkyl; R 2 is hydrogen, lower alkyl or cycloalkyl R 3 -R 7 are hydrogen, lower alkyl, lower alkoxy, hydroxy or R 3 and R 4 taken together are -(CH 2 ) n - or R 6 and R 7 taken together are -OCH 2 O- and n is 3 or 4, as well as pharmaceutically acceptable salts for the manufacture of medicaments for the control or treatment of diseases which represent therapeutic indications for NMDA receptor subtype specific blockers.
摘要:
The present invention relates to the use of compounds of the general formula wherein
Ar 1 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by hydroxy, lower alkoxy, nitro, amino or methanesulfonamide; Ar 2 is phenyl, naphthyl or tetrahydronaphthyl, optionally substituted by lower alkyl or halogen; X is C, CH, C(OH) or N; Y is -CH 2 -, CH or O Z -CH 2 -, -CH(CH 3 )- or -C(CH 3 ) 2 -; R 1 is hydrogen, lower alkyl or acetyl; A is C=O or -(CHR 2 ) n -, wherein R 2 is hydrogen, lower alkyl or hydroxy-lower alkyl; B is -(CH 2 ) n -, O, -CH(OH)(CH 2 ) n -, -CH(CH 2 OH)(CH 2 ) n -, -(CH 2 ) n CH(OH)- or -CH(CH 2 OH)-; --- may be a bond and n is 0-4 and to pharmaceutically acceptable acid addition salts thereof for the manufacture of medicaments which represent therapeutic indications for NMDA receptor subtype specific blockers.
摘要:
The present invention provides the use of compounds of general formula I and compounds of general formula II as modulators and affinity labels of the MPTP complex. Furthermore, the present invention provides methods for modulating the activity of the MPTP complex, methods for determining the presence of a component of the MPTP complex, and methods for identifying an active agent that modulates the activity of the MPTP complex, specifically methods for identifying an active agent that modulates the activity of the MPTP complex by interacting with the VDAC1 component. Moreover, novel compounds of general formula I are provided by the present invention.